MARÍA DEL CARMEN GARRIDO NAVAS-rekin lankidetzan egindako argitalpenak (13)

2022

  1. Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior

    Theranostics, Vol. 12, Núm. 5, pp. 2150-2161

  2. Hepatocellular carcinoma risk-stratification based on ASGR1 in circulating epithelial cells for cancer interception

    Frontiers in Molecular Biosciences, Vol. 9

  3. Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective

    Molecular Genetics and Genomics, Vol. 297, Núm. 3, pp. 859-871

2021

  1. Cross‐resistance to abiraterone and enzalutamide in castration resistance prostate cancer cellular models is mediated by ar transcriptional reactivation

    Cancers, Vol. 13, Núm. 6, pp. 1-21

  2. Deep phenotypic characterisation of CTCs by combination of microfluidic isolation (Isoflux) and imaging flow cytometry (imagestream)

    Cancers, Vol. 13, Núm. 24

2020

  1. From precision medicine to imprecision medicine through limited diagnostic ability to detect low allelic frequency mutations

    Translational Lung Cancer Research, Vol. 9, Núm. 2, pp. 180-183

  2. Liquid biopsy and prostate cancer. Current evidence applied to clinical practice

    Actas Urologicas Espanolas, Vol. 44, Núm. 3, pp. 139-147

  3. Precision prevention and cancer interception: The new challenges of liquid biopsy

    Cancer Discovery, Vol. 10, Núm. 11, pp. 1635-1644

  4. The polemic diagnostic role of TP53 mutations in liquid biopsies from breast, colon and lung cancers

    Cancers, Vol. 12, Núm. 11, pp. 1-17

2019

  1. Cooperative and Escaping Mechanisms between Circulating Tumor Cells and Blood Constituents

    Cells, Vol. 8, Núm. 11

  2. Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy

    Breast Cancer Research, Vol. 21, Núm. 1

  3. Liquid biopsy beyond of cancer: Circulating pulmonary cells as biomarkers of COPD aggressivity

    Critical Reviews in Oncology/Hematology, Vol. 136, pp. 31-36

2018

  1. Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients

    Journal of Translational Medicine, Vol. 16, Núm. 1